DETECTING NOVEL BIOMARKERS FOR OVARIAN CANCER

DETECTING NOVEL BIOMARKERS FOR OVARIAN CANCER

DETECTING NOVEL BIOMARKERS FOR OVARIAN CANCER: ROLE OF RAD51AP1

Authors: Vincent Ruttoh1,2, Emmanouil Karteris2, Dimple Chudasama2

Affiliations

  1. Kenya Medical Research Institute (KEMRI)
  2. Brunel University, London

Ovarian carcinoma is the most lethal gynecologic malignancy in developed countries with a five-year survival rate of less than 40%. This is due to the asymptomatic nature of ovarian cancer and lack of reliable assay that can be used in early diagnosis hence 80% of the cases are detected in stages III or IV when the chances of a 5-year survival has diminished. Despite advances in treatment options, the treatment outcomes for patients have remained largely unchanged over the past few decades. There is no single molecular profile that has been that has been able to overcome the limitations of CA125.

Using microarray data of multiple cancer studies and a combination of in silico networks, we first derived a unique-network for ovarian cancer and then identified the genes that are uniquely involved in this mechanism.  RAD51AP1 was one of the genes identified.  Ovarian tissue microarrays were then analyzed immunohistochemically for protein expression of RAD51AP1. Patient serum was then analyzed using quantitative RT-PCR to measure gene expression RAD51AP1.

RAD51AP1 was expressed constitutively in all serous papillary carcinoma tissues Immunohistochemical analysis of ovarian and lung cancer tissues and unaffected controls demonstrated that significant quantitative and qualitative change in RAD51AP1 protein expression between normal and cancerous tissues. Significant expression was also observed between tumour grade and RAD51AP1 protein expression. qRT-PCR results showed that RAD51AP1 was overexpressed in blood samples of ovarian cancer patients compared to healthy controls.

RAD51AP1 is a promising prognostic and/or predictive biomarker candidate. Its role in ovarian cancer oncogenesis should be studied further before being validated for clinical use.

 

Presenter: Mr. Vincent Ruttoh

Affiliation: Kenya Medical Research Institute

Share this post

Leave a Reply

Your email address will not be published. Required fields are marked *